Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook

Oscar Health, Inc. (OSCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook New York, NY, August 6, 2026 – Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR) announced today its financial results for

Event · Earnings
Also in this documentGuidance · raise · $18.7B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 6, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$OSCR
Bullish
high confidence
Mentioned
$OSCR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OSCRBullishHigh
01

Why it matters

Oscar’s Q2 profitability and operating metrics improved sharply year over year, and management raised FY2026 guidance for revenue, MLR, SG&A ratio, and operating earnings, creating a direct repricing catalyst.

02

Market read

This is a primary-source earnings and guidance update with quantified KPI changes (revenue, MLR, SG&A ratio, operating income) and updated FY2026 ranges.

03

What to watch

Traders should scrutinize the updated MLR and SG&A guidance ranges and whether membership growth assumptions hold, especially given the prior Cigna+Oscar partnership ended in 2024.

Relevance 7/10Novelty 9/10Timing: today’s 8-K earnings and updated FY2026 guidance, conference call at 8:00 a.m. ET
AlphAI · Earnings readOSCR · second quarter 2026 · ended June 30, 2026

Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook

✓Strong quarter

Second-quarter revenue, underwriting metrics, operating earnings, net income, diluted earnings per share, and Adjusted EBITDA all improved versus the second quarter of 2025, while the Company raised its full-year outlook for medical loss ratio, SG&A expense ratio, and earnings from operations.

Revenue
$4.88B
EPS · GAAP
$1.10 of diluted earnings
Updated Full Year 2026 Outlook outlook
$18.7 billion to $19.0 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended June 30, 2026GAAP$4.88B––
Medical loss ratio, three months ended June 30, 2026other79.2%––
SG&A expense ratio, three months ended June 30, 2026other14.2%––
Earnings from operations, three months ended June 30, 2026GAAP$388.6M––
Net income attributable to Oscar Health, Inc., three months ended June 30, 2026GAAP$361.8M––
Diluted earnings per share, three months ended June 30, 2026GAAP$1.10 of diluted earnings per share––
Adjusted EBITDA, three months ended June 30, 2026non-GAAP$415.3M––
Total revenue, six months ended June 30, 2026GAAP$9.53B––
Medical loss ratio, six months ended June 30, 2026other75.0%––
SG&A expense ratio, six months ended June 30, 2026other14.7%––
Earnings from operations, six months ended June 30, 2026GAAP$1.09B––
Net income attributable to Oscar Health, Inc., six months ended June 30, 2026GAAP$1.04B––
Adjusted EBITDA, six months ended June 30, 2026non-GAAP$1.14B––
Individual and Small Group effectuated membership as of June 30, 2026other2,963,002––
Cigna+Oscar effectuated membership as of June 30, 2026other—––
Total effectuated members as of June 30, 2026other2,963,002––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Updated Full Year 2026 Outlook outlook

  • Revenue$18.7 billion to $19.0 billion
  • NoteMedical Loss Ratio: 81.5% to 82.5%
  • NoteSG&A Expense Ratio: 15.6% to 16.1%
  • NoteEarnings from Operations: $500 million to $700 million

What drove it

  • Total revenue growth was driven by higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual.
  • The medical loss ratio decrease was primarily driven by disciplined pricing strategy and $164 million of favorable prior period reserve development.
  • The SG&A expense ratio decrease was primarily due to disciplined expense management, greater fixed cost leverage, and the impact of lower risk adjustment as a percentage of premium.
  • The increase in earnings from operations reflected strong operating performance driven primarily by improved underwriting performance and favorable prior period development.

Concerns

  • Second-quarter total revenue growth was partially offset by an increase in the net risk adjustment transfer accrual.
  • The second quarter of 2025 medical loss ratio included the entire first half impact of 2025 risk adjustment true-up driven by higher average market morbidity.
  • The Company identified risks relating to changes in federal or state laws or regulations, including the expiration of enhanced Advanced Premium Tax Credits, implementation of new program integrity rules pursuant to the Notice of Benefit and Payment Parameters for policy year 2027, and potential funding of a cost-sharing reduction program.
  • The Company identified risks relating to accurately estimating incurred medical expenses or overall market morbidity, risk adjustment programs, capital reserve and surplus requirements, and quota share reinsurance.

What to watch

  • Medical loss ratio performance against the updated full-year range of 81.5% to 82.5%.
  • SG&A expense ratio performance against the updated full-year range of 15.6% to 16.1%.
  • Earnings from operations performance against the updated full-year range of $500 million to $700 million.
  • Membership growth, rate increases, net risk adjustment transfer accruals, and prior period reserve development.

Analysis

Oscar reported substantial second-quarter improvement across revenue, underwriting and profitability. Total revenue was $4,880,220 (in thousands), compared with $2,863,945 (in thousands) in the second quarter of 2025. The Company attributed the increase to higher membership and rate increases, partially offset by an increase in the net risk adjustment transfer accrual. Total effectuated members were 2,963,002 as of June 30, 2026, compared with 2,027,148 as of June 30, 2025.

Underwriting and expense ratios improved materially. The medical loss ratio was 79.2%, compared with 91.1%, with the Company citing disciplined pricing strategy and $164 million of favorable prior period reserve development. The prior-year quarter included the entire first half impact of the 2025 risk adjustment true-up driven by higher average market morbidity. The SG&A expense ratio was 14.2%, compared with 18.7%, reflecting disciplined expense management, greater fixed cost leverage, and lower risk adjustment as a percentage of premium.

The improved operating profile produced earnings from operations of $388,635 (in thousands), compared with a loss from operations of $(230,483) (in thousands). Net income attributable to Oscar Health, Inc. was $361,808 (in thousands), or $1.10 of diluted earnings per share, compared with a net loss attributable to Oscar Health, Inc. of $(228,361) (in thousands), or $(0.89) of diluted earnings per share. Adjusted EBITDA was $415,349 (in thousands), compared with an Adjusted EBITDA loss of $(199,404) (in thousands). For the six months ended June 30, 2026, earnings from operations were $1,092,720 (in thousands), net income attributable to Oscar Health, Inc. was $1,040,804 (in thousands), and Adjusted EBITDA was $1,142,421 (in thousands).

The updated full-year outlook retains total revenue of $18.7 billion to $19.0 billion while improving the medical loss ratio range to 81.5% to 82.5% from 82.4% to 83.4%, the SG&A expense ratio range to 15.6% to 16.1% from 15.8% to 16.3%, and earnings from operations to $500 million to $700 million from $250 million to $450 million. The guide places the key focus on whether pricing discipline, membership growth, expense leverage and reserve development can support the improved full-year operating targets amid risk adjustment and regulatory uncertainty.

Management, verbatim

Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance.

Mark Bertolini, CEO of Oscar Health

Our superior operating performance and execution against the fundamentals of our strategy are accelerating the individual market.

Mark Bertolini, CEO of Oscar Health

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported financial metrics
  • Printed year-over-year percentage changes for reported financial metrics
  • Gross margin
  • Gross-margin guidance
  • Operating expenses as a dollar amount
  • Operating-expenses guidance
  • Tax rate
  • Tax-rate guidance
  • Cash and cash equivalents
  • Debt
  • Operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Segment revenue disclosures
  • Prior-release outlook for comparison to actual results

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The 8-K includes Item 2.02 results for Q2 2026 and an updated full-year 2026 outlook, framed around improved underwriting and disciplined pricing.

Company-level read

Ticker impact

$OSCRBullishHigh confidence
Context

Oscar reported Q2 2026 results with revenue up to $4.88B, MLR down to 79.2%, and raised full-year 2026 guidance.

Expected impact

Likely positive near-term bias as traders reprice FY2026 earnings power; follow-through depends on whether MLR improvement persists beyond prior-period reserve effects.

Evidence & confidence

The filing is a fresh 8-K with updated FY2026 outlook and multiple Q2 operating KPI improvements (MLR, SG&A ratio, operating income, net income).

Market effects

Reinforces the narrative that profitable individual-market insurers can expand margins via disciplined pricing and expense leverage, potentially supporting sector sentiment.

No specific regional impact disclosed beyond US individual health insurance dynamics.

Limited, as the disclosure is company-specific to US healthcare insurance operations.

Counterpoint

MLR improvement may be partly driven by favorable prior-period reserve development, which could reverse and cap forward margin durability.

Key entities

  • Oscar Health, Inc.

    US health insurer reporting Q2 2026 results and raising full-year 2026 guidance in an SEC 8-K.

  • Mark Bertolini

    CEO quoted emphasizing record profitability and raised full-year 2026 outlook.

Every OSCR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.